Ix Therapeutics GmbH is a joint venture founded by Xlife Sciences AG and Indivumed GmbH in March 2021.

Ix Therapeutics GmbH is dedicated to identifying therapeutic antibodies for oncological indications based on multiomics patient data. Ix Therapeutics is a joint venture between Xlife Sciences AG and the Hamburg-based oncology company Indivumed. The therapeutic antibodies are identified using Veraxa's screening technology.

For more information, please visit: www.ix-therapeutics.com